FDA granted accelerated approval to dostarlimab-gxly for dMMR or MSI-H locally advanced rectal cancer based on interim phase 2 AZUR-1 results.
|Articles|January 1, 2002
Supplements and Featured Publications
- Symposium Reporter - Lipid Management
- Volume 8
- Issue 1 Symp
Lipid-Lowering Therapy Stabilizes Plaque Reduces Events by Limiting Inflammation
Author(s)Peter Libby, MD
Advertisement
Articles in this issue
almost 25 years ago
Review of Clinical trial Data Reaffirms Safety of Statin Therapyalmost 25 years ago
Protective Effects of HDL-C and Need to Raise Low Levels Exploredalmost 25 years ago
Question and Answeralmost 25 years ago
New Cholesterol Guidelines Emphasize Risk AssessmentAdvertisement
Related to this article
Phentolamine 0.75% (Ryzumvi) won FDA approval for presbyopia based on the phase 3 VEGA-2 and VEGA-3 trials.
Nearly 3 in 4 bariatric surgery candidates had clinical obesity, a phenotype that BMI alone did not distinguish from preclinical obesity.
Satralizumab, a first-in-class IL-6 receptor inhibitor, was approved for adults with thyroid eye disease based on the phase 3 SatraGO program.
A review of 47 endometriosis guidelines found most came from high-income settings and diverged on biomarkers, repeat surgery, and fertility referral.
The meeting covered several topics in eye care, including how artificial intelligence (AI) can play a part in eye care.
A meta-analysis of 27 trials found a 15% cardiovascular risk reduction per 10-mm Hg lower systolic BP, with no added risk of kidney failure.
In a Japanese registry of 1235 patients with AMI treated with PCI, Lp(a) of 24 mg/dL or higher independently predicted MACE and HF hospitalization.
Advertisement
Advertisement
Trending on AJMC
1
Pathological Response Does Not Reliably Predict Survival in Sarcoma
2
New CHEST Guidelines Offer a Road Map for Bronchiectasis
3
CHEST Investigations Explore COPD Guideline Adherence, Adding Ensifentrine, and Use of AI in Education
4
CHEST Highlights Practice-Changing COPD Therapy and Strategies
5